

RAINBOW.

RAINBOW CAPITAL (HK) LIMITED
滋博資本有限公司

Date: 24 June 2026

Sisram Medical Ltd (the “Company”)

HaHarash Street 18
Industrial Park
Caesarea 3079895
Israel

Dear Sir/Madam,

**RE: CONTINUING CONNECTED TRANSACTION RELATING TO THE NEW
SUPPLY FRAMEWORK AGREEMENT**

We refer to the circular of the Company dated 24 June 2026 (the “Circular”) in connection with the New Supply Framework Agreement. Unless otherwise stated, terms defined in the Circular have the same meanings in this letter.

We confirm that as at the Latest Practicable Date, (i) we did not have any direct or indirect shareholding in any member of the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for shares in any member of the Group; and (ii) we did not have any direct or indirect interests in any assets which have been, since 31 December 2025 (being the date to which the latest published audited consolidated financial statements of the Group were made up), acquired or disposed of by or leased to any member of the Group, or which are proposed to be acquired or disposed of by or leased to any member of the Group.

We hereby further give our consent and confirm that we have not withdrawn our consent to the issue of the Circular by the Company, and the inclusion therein of all references to our name (including our qualification) and our letter, report or opinion, in the form and context in which they are respectively included in the Circular.

We hereby consent to our letters being made available for display as described in the Circular.

Yours faithfully,

For and on behalf of
Rainbow Capital (HK) Limited



Name: Danny Leung
Title: Managing Director